Cytosorbents Corporation · NASDAQ:CTSO
Cytosorbents — Q2 2014 Earnings Presentation
29 slides from Cytosorbents's earnings presentation, Aug 15, 2014
Slide 1: An Emerging Leader in Critical Care Immunotherapy: Q2 2014 Review
Cyto Sorbents Corporation OTCBB: CTSO An Emerging Leader in Critical Care Immunotherapy Q2 2014 Review – August 12, 2014
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiary CytoSorbents, Inc that are not historical facts are forward - looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ
Slide 3: Conference Call Participants
3 Conference Call Participants Dr . Phillip Chan, MD, PhD Chief Executive Officer and President Vincent Capponi, MS Chief Operating Officer Kathleen Bloch, MBA, CPA Chief Financial Officer Dr . Christian Steiner, MD Vice President of Sales and Marketing Christopher Cramer, MS, MBA Vice President of
Slide 4: Emerging Leader in the $20B Critical Care Immunotherapy Space
4 Cyto Sorbents is an Emerging Leader in the $20B Critical Care Immunotherapy Space Leading the Prevention or Treatment of Life - Threatening Inflammation in the ICU
Slide 5: Inflammation Plays a Major Role in Nearly Every Known Disease
5 Inflammation Plays a Major Role in Nearly Every Known Disease • Life threatening conditions like sepsis & trauma • Autoimmune diseases like rheumatoid arthritis, inflammatory bowel, psoriasis, and lupus • Heart disease, peripheral artery disease • Cancer, cancer cachexia, graft vs host disease • N
Slide 6: Severe Inflammation Drives Organ Failure
6 Severe Inflammation Drives Organ Failure Organ failure occurs when vital organs stop working, causing nearly half of all deaths in the ICU, but little can be done to treat or prevent it today
Slide 7: CytoSorb Removes the Fuel to the Fire
7 Cyto Sorb ® Removes the Fuel to the Fire • CytoSorb ® represents a powerful immunotherapy to control inflammation • Approved in the European Union as the only specifically approved extracorporeal cytokine filter • Clinically proven to reduce key cytokines in blood in critically - ill patients • Ap
Slide 8: The Heart of the Technology
8 The Heart of the Technology The underlying blood purification technology is based on state - of - the - art biocompatible, highly porous polymer beads that act like tiny sponges to remove harmful substances from blood • Protected by 32 issued US patents and multiple applications pending • Manufact
Slide 9: Goal: To Prevent or Treat Organ Failure
9 Goal: To Prevent or Treat Organ Failure Sepsis ARDS Burn Injury Trauma Pancreatitis Influenza Surgical The Potential to Revolutionize Critical Care Medicine Improve Patient Outcome and Survival Decrease Costs Of ICU and Patient Care
Slide 10: CytoSorb Marketed in 19 Countries
10 Available for sale in all 28 countries in the EU. Sold direct in Germany, Austria, and Switzerland. Established distribution in the UK, Ireland, Netherlands, Turkey, Russia, India, Taiwan, and Middle East covering ~1.7 billion lives. Expanding to other EU countries and countries outside the EU th
Slide 11: $15+ Million in US Government Support
11 • US Dept of Health and Human Services awarded $0.5M grant (2010) for therapies that can save lives and reduce costs under the QTDP Program • NIH grant awarded $7M five year (2006 - 2010) to University of Pittsburgh and Dr. John Kellum to research CytoSorb bead for treatment of sepsis • NIH/NHLBI
Slide 12: Q2 2014 Operating and Financial Highlights
12 Q2 2014 Operating and Financial Highlights
Slide 13: First Half Comparative Revenue Results
13 First Half Comparative Revenue Results • First half 2014 total revenue of approximately $2.1M, an increase of 215% compared to total revenues of approximately $663K for the first half of 2013. • First half 2014 product sales were approximately $1.2M, an increase of 305% over first half 2013 produ
Slide 14: Q2 2014 Comparative Revenue Results
14 Q2 2014 Comparative Revenue Results • Second quarter 2014 total revenue of approximately $1.0M, an increase of 252% compared to total revenues of approximately $291K for the second quarter of 2013. • Product sales for the second quarter of 2014 product sales were approximately $663K, an increase
Slide 15: Continuing Strong Product Growth
15 Continuing Strong Product Growth $13,679 $87,960 $176,098 $127,969 $203,561 $314,159 $569,243 $663,233 $0 $100,000 $200,000 $300,000 $400,000 $500,000 $600,000 $700,000 Q3 2012 Q4 2012 Q1 2013 Q2 2013 Q3 2013 Q4 2013 Q1 2014 Q2 2014 CytoSorb ® Product Sales Q2 2014 is the fourth consecutive quart
Slide 16: Product Sales (TTM)
16 Product Sales (TTM) $151,574 $310,779 $405,706 $595,588 $821,787 $1,214,932 $1,750,196 $- $200,000 $400,000 $600,000 $800,000 $1,000,000 $1,200,000 $1,400,000 $1,600,000 $1,800,000 $2,000,000 Q4 2012 Q1 2013 Q2 2013 Q3 2013 Q4 2013 Q1 2014 Q2 2014 Trailing Twelve Month Product Sales Trend Line
Slide 17: The Path to Up-listing
17 The Path to Up - listing Completed: x Met with NYSE and NASDAQ x Evaluation of listing requirements x Transitioned to a new SEC counsel to provide guidance during up - listing process x Adopted Code of Business Conduct and Ethics x Updating our Insider Trading Policy x Improvements to our system
Slide 18: U.S. Cardiac Surgery Pivotal Trial
18 U.S. Cardiac Surgery Pivotal Trial
Slide 19: Cardiac Surgery Stats
19 Cardiac Surgery Stats Approximately 1MM Cardiopulmonary Bypass Surgeries in US and EU annually • Coronary artery bypass graft surgery • Open valve repair, cardiac defect repair • Heart or lung transplantation • LVAD implantation Patients often develop inflammation due to cytokine storm, complemen
Slide 20: Intra-operative versus Post-Operative
20 Intra - operative versus Post - Operative
Slide 21: U.S. Cardiac Surgery Pivotal Trial
21 U.S. Cardiac Surgery Pivotal Trial 2 1 1) Inflammatory Biomarker Reduction • Randomized controlled multi - center trial <150 patients • Enrich for cardiac surgery patients at high risk for inflammation and hemolysis and treat DURING surgery with CytoSorb in a bypass circuit • Primary endpoint: Re
Slide 22: KardioTechnik 2014 Retrospective Cardiac Surgery Study
22 KardioTechnik 2014 Retrospective 40 patient cardiac surgery study • 20 patient (with CytoSorb) vs 20 patient (without CytoSorb) used intra - operatively with heart - lung machine • Patients underwent high risk surgery with hypothermic cardiac arrest and anterograde cerebral perfusion • Treatment
Slide 23: Ebola Virus
23 Ebola Virus • Ebola is one of the most deadly viruses known with a very high mortality rate of 50 - 90% depending upon the strain, and very contagious (bodily fluids) • Following an incubation phase of 2 - 21 days, has an abrupt onset of symptoms including high fever, chills, weakness and body pa
Slide 24: Could CytoSorb Help?
24 Could Cyto Sorb ® Help? The 2014 Ebola epidemic in West Africa, called an “international emergency” by the WHO, continues to grow and has already infected nearly 1,900 people, and claimed more than 1,000 lives. Epidemic is expected to continue throughout the year. Our Strategy for outreach: • WHO
Slide 25: Our Bead Technology Enables a Diverse and Valuable Pipeline
25 Critical Care, High Risk Surgery Our Bead Technology Enables a Diverse and Valuable Pipeline Blood Collection & Transfusion CT Imaging, Interventional Radiology Contrast Sorb Drug Overdose, Chemo Removal Drug Sorb Beta Sorb Improving Dialysis Under Development CE Mark Approved
Slide 26: Potential for Strategic Partnerships
26 Potential for Strategic Partnerships* Cardiac Surgery Renal Dialysis Blood Transfusion Biotech and Immunotherapy Critical Care or Catheters *Companies listed here are used simply as examples of companies in these respective verticals. We make no other representations to our relationship with any
Slide 27: Acute Graft Dysfunction Case Report
27 Acute Graft Dysfunction Case Report Acute graft dysfunction after liver transplantation is a life - threatening event and requires emergency re - transplantation. The inflammatory response is responsible for most of the systemic complications and increased mortality • 46 year old man with a histo
Slide 28: Toxic Shock Syndrome Case Report
28 Toxic Shock Syndrome Case Report • 17 year old man suffered an injury to his ankle and unexpectedly began to develop fever • He rapidly deteriorated and was hospitalized the next day at a major hospital in Rotterdam, Netherlands where antibiotics were started immediately. He continued to decline
Slide 29: Contact and Q&A Session
29 Phillip P. Chan, MD, PhD - CEO 7 Deer Park Drive, Suite K Monmouth Junction, NJ 08852 pchan@cytosorbents.com Cyto Sorbents Corporation OTCBB: CTSO The Rise of An Emerging Critical Care Immunotherapy Company Q&A Session